Anahad O’Connor, writing for the New York Times, covers Amarin’s powerful fish oil drug, Vascepa.  The Times writer noted cardiologists may one day have a new tool to help prevent heart attacks and strokes in some high-risk patients: a prescription drug that contains large doses of EPA, an omega-3 fatty acid contained in fish oil. A large clinical trial found that Vascepa, sharply reduced the rate of cardiovascular events in people with a history of heart disease or Type 2 diabetes, according to early results.

The study showed that adults who were given high doses of the purified EPA had a 25% reduction in their risk of heart attack, stroke, etc.

Source: New York Times

Pin It on Pinterest